| __timestamp | Exelixis, Inc. | Ultragenyx Pharmaceutical Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 50829000 | 10811000 |
| Thursday, January 1, 2015 | 57305000 | 33001000 |
| Friday, January 1, 2016 | 116145000 | 64936000 |
| Sunday, January 1, 2017 | 159362000 | 99909000 |
| Monday, January 1, 2018 | 206366000 | 127724000 |
| Tuesday, January 1, 2019 | 228244000 | 161524000 |
| Wednesday, January 1, 2020 | 293355000 | 182933000 |
| Friday, January 1, 2021 | 401715000 | 219982000 |
| Saturday, January 1, 2022 | 459856000 | 278139000 |
| Sunday, January 1, 2023 | 542705000 | 309799000 |
| Monday, January 1, 2024 | 492128000 |
Data in motion
In the competitive world of biotechnology, managing Selling, General, and Administrative (SG&A) expenses is crucial for maintaining profitability and operational efficiency. From 2014 to 2023, Exelixis, Inc. and Ultragenyx Pharmaceutical Inc. have shown distinct trends in their SG&A expenditures. Exelixis has seen a significant increase, with expenses growing by over 900% from 2014 to 2023. In contrast, Ultragenyx's SG&A costs have risen by approximately 186% over the same period. This stark difference highlights Exelixis's aggressive expansion strategy, while Ultragenyx appears to maintain a more conservative approach. As investors and stakeholders evaluate these companies, understanding their cost management strategies provides valuable insights into their long-term sustainability and growth potential.
Amgen Inc. and Ultragenyx Pharmaceutical Inc.: SG&A Spending Patterns Compared
Viatris Inc. vs Exelixis, Inc.: SG&A Expense Trends
Who Optimizes SG&A Costs Better? Bio-Techne Corporation or Ultragenyx Pharmaceutical Inc.
SG&A Efficiency Analysis: Comparing Sarepta Therapeutics, Inc. and Exelixis, Inc.
Cost Management Insights: SG&A Expenses for Exelixis, Inc. and Ascendis Pharma A/S
Research and Development: Comparing Key Metrics for Exelixis, Inc. and Ultragenyx Pharmaceutical Inc.
SG&A Efficiency Analysis: Comparing Exelixis, Inc. and Ionis Pharmaceuticals, Inc.
Exelixis, Inc. and Perrigo Company plc: SG&A Spending Patterns Compared
Exelixis, Inc. and Veracyte, Inc.: SG&A Spending Patterns Compared
Selling, General, and Administrative Costs: Exelixis, Inc. vs Geron Corporation
Cost Management Insights: SG&A Expenses for Ultragenyx Pharmaceutical Inc. and Rhythm Pharmaceuticals, Inc.
Breaking Down SG&A Expenses: Ultragenyx Pharmaceutical Inc. vs MiMedx Group, Inc.